세계의 항암제 단클론항체(mAb) 시장 규모 조사 및 예측 : 유형별, 용도별, 최종 사용자별, 지역별 분석(2023-2030년)

Global Anticancer monoclonal antibodies Market is valued at approximately USD XX billion in 2022 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2023-2030. Anti-cancer monoclonal antibodies are made to specifically target and bind to antigens expressed on cancer cells or in the tumour microenvironment. These antibodies can influence the body's immunological response to cancer cells, suppress tumour development, boost the immune system's ability to fight cancer, and transport cytotoxic chemicals directly to tumour cells, among other processes. The market for anti-cancer MAbs is being driven by factors such as the rising incidence and prevalence of cancer in the globe, the expanding knowledge of cancer biology and the discovery of novel therapeutic targets, and improvements in biotechnology and antibody engineering methods.

The American Society of Clinical Oncology predicts that by the end of 2022, there have been 1.9 million cancer diagnoses and 609,360 cancer-related deaths in the United States. Additionally, estimations from the same source suggested that 176,000 people had multiple myeloma diagnoses globally in 2020. More than 34,000 people given a multiple myeloma diagnosis in 2022, and more than 12,000 people expected to pass away in the United States. More than a dozen monoclonal antibodies have received FDA approval in the last few years to treat different cancers. Furthermore, GamaMabs Pharma SA was purchased by Exelixis Inc., a USD 5 million genomics-based drug development company, in May 2021. Exelixis Inc. intends to expand its current therapeutic product range of GamaMabs and related manufacturing cell lines by acquiring GamaMabs' AMHR2 antibody technology. The biotechnology company GamaMabs Pharma SA is established in France and is dedicated to creating novel monoclonal antibodies for the treatment of solid tumours. However, the high cost of treatment and side Effects and Safety Concerns stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Anticancer monoclonal antibodies Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America is the leading region owing to rising strategies such as partnership and collaboration. However, Asia Pacific is expected to be the fastest growing region due to the increasing number of international and national collaborations among entities, especially those in developed and developing countries, which is expected to propel the market.

Major market players included in this report are:

• Amgen Inc.
• Bristol Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Genmab AS
• Novartis AG
• Merck & Co., Inc.
• GlaxoSmithKline plc
• Johnson & Johnson Corp.
• AbbVie, Inc.

Recent Developments in the Market:

• In May 2022, PHESGO was introduced by Roche Holding AG, a pharmaceutical business located in Switzerland. Pertuzumab, trastuzumab, and hyaluronidase-zzxf, or PHESGO, is a novel monoclonal antibody (mAb) combination therapy for early breast cancer that is HER2-positive. The two monoclonal antibodies (mAbs) pertuzumab and trastuzumab, along with the enzyme hyaluronidase, are administered subcutaneously (under the skin).
• In 2021, GamaMabs Pharma SA was purchased by Exelixis Inc., a genomics-based medicine discovery business with headquarters in the US, for USD 5 million. Exelixis Inc. intends to expand its current therapeutic product range of GamaMabs and related manufacturing cell lines by acquiring GamaMabs' AMHR2 antibody technology.

Global Anticancer monoclonal antibodies Market Report Scope:

• Historical Data: 2020 - 2021
• Base Year for Estimation: 2022
• Forecast period: 2023-2030
• Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Segments Covered: Type, Application, End User, Region
• Regional Scope: North America; Europe; Asia Pacific; Latin America; Middle East & Africa
• Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which expected to define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Type:

• Murine Antibodies
• Chimeric Antibodies
• Humanized Antibodies
• Other Types

By Application:

• Blood Cancer
• Breast Cancer
• Lung Cancer
• Melanoma
• Colorectal Cancer
• Liver Cancer
• Other Applications

By End User:

• Hospitals
• Research Institutes
• Other End Users

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

• 1.1. Market Snapshot
• 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
  • 1.2.1. Anticancer monoclonal antibodies Market, by Region, 2020-2030 (USD Billion)
  • 1.2.2. Anticancer monoclonal antibodies Market, by Type, 2020-2030 (USD Billion)
  • 1.2.3. Anticancer monoclonal antibodies Market, by Application, 2020-2030 (USD Billion)
  • 1.2.4. Anticancer monoclonal antibodies Market, by End User, 2020-2030 (USD Billion)
• 1.3. Key Trends
• 1.4. Estimation Methodology
• 1.5. Research Assumption

Chapter 2. Global Anticancer monoclonal antibodies Market Definition and Scope

• 2.1. Objective of the Study
• 2.2. Market Definition & Scope
  • 2.2.1. Industry Evolution
  • 2.2.2. Scope of the Study
• 2.3. Years Considered for the Study
• 2.4. Currency Conversion Rates

Chapter 3. Global Anticancer monoclonal antibodies Market Dynamics

• 3.1. Anticancer monoclonal antibodies Market Impact Analysis (2020-2030)
  • 3.1.1. Market Drivers
    • 3.1.1.1. Increase in prevalence of cancer
    • 3.1.1.2. Increase in growth of Pharmaceutical Industry
  • 3.1.2. Market Challenges
    • 3.1.2.1. High cost of treatment
    • 3.1.2.2. Side Effects and Safety Concerns
  • 3.1.3. Market Opportunities
    • 3.1.3.1. Development of Novel Targets
    • 3.1.3.2. Integration of anti-cancer MAbs with other immunotherapies

Chapter 4. Global Anticancer monoclonal antibodies Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
• 4.2. Porter's 5 Force Impact Analysis
• 4.3. PEST Analysis
  • 4.3.1. Political
  • 4.3.2. Economical
  • 4.3.3. Social
  • 4.3.4. Technological
  • 4.3.5. Environmental
  • 4.3.6. Legal
• 4.4. Top investment opportunity
• 4.5. Top winning strategies
• 4.6. COVID-19 Impact Analysis
• 4.7. Disruptive Trends
• 4.8. Industry Expert Perspective
• 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Anticancer monoclonal antibodies Market, by Type

• 5.1. Market Snapshot
• 5.2. Global Anticancer monoclonal antibodies Market by Type, Performance - Potential Analysis
• 5.3. Global Anticancer monoclonal antibodies Market Estimates & Forecasts by Type 2020-2030 (USD Billion)
• 5.4. Anticancer monoclonal antibodies Market, Sub Segment Analysis
  • 5.4.1. Murine Antibodies
  • 5.4.2. Chimeric Antibodies
  • 5.4.3. Humanized Antibodies
  • 5.4.4. Other Types

Chapter 6. Global Anticancer monoclonal antibodies Market, by Application

• 6.1. Market Snapshot
• 6.2. Global Anticancer monoclonal antibodies Market by Application, Performance - Potential Analysis
• 6.3. Global Anticancer monoclonal antibodies Market Estimates & Forecasts by Application 2020-2030 (USD Billion)
• 6.4. Anticancer monoclonal antibodies Market, Sub Segment Analysis
  • 6.4.1. Blood Cancer
  • 6.4.2. Breast Cancer
  • 6.4.3. Lung Cancer
  • 6.4.4. Melanoma
  • 6.4.5. Colorectal Cancer
  • 6.4.6. Liver Cancer
  • 6.4.7. Other Applications

Chapter 7. Global Anticancer monoclonal antibodies Market, by End User

• 7.1. Market Snapshot
• 7.2. Global Anticancer monoclonal antibodies Market by End User, Performance - Potential Analysis
• 7.3. Global Anticancer monoclonal antibodies Market Estimates & Forecasts by End User 2020-2030 (USD Billion)
• 7.4. Anticancer monoclonal antibodies Market, Sub Segment Analysis
  • 7.4.1. Hospitals
  • 7.4.2. Research Institutes
  • 7.4.3. Other End Users

Chapter 8. Global Anticancer monoclonal antibodies Market, Regional Analysis

• 8.1. Top Leading Countries
• 8.2. Top Emerging Countries
• 8.3. Anticancer monoclonal antibodies Market, Regional Market Snapshot
• 8.4. North America Anticancer monoclonal antibodies Market
  • 8.4.1. U.S. Anticancer monoclonal antibodies Market
    • 8.4.1.1. Type breakdown estimates & forecasts, 2020-2030
    • 8.4.1.2. Application breakdown estimates & forecasts, 2020-2030
    • 8.4.1.3. End User breakdown estimates & forecasts, 2020-2030
  • 8.4.2. Canada Anticancer monoclonal antibodies Market
• 8.5. Europe Anticancer monoclonal antibodies Market Snapshot
  • 8.5.1. U.K. Anticancer monoclonal antibodies Market
  • 8.5.2. Germany Anticancer monoclonal antibodies Market
  • 8.5.3. France Anticancer monoclonal antibodies Market
  • 8.5.4. Spain Anticancer monoclonal antibodies Market
  • 8.5.5. Italy Anticancer monoclonal antibodies Market
  • 8.5.6. Rest of Europe Anticancer monoclonal antibodies Market
• 8.6. Asia-Pacific Anticancer monoclonal antibodies Market Snapshot
  • 8.6.1. China Anticancer monoclonal antibodies Market
  • 8.6.2. India Anticancer monoclonal antibodies Market
  • 8.6.3. Japan Anticancer monoclonal antibodies Market
  • 8.6.4. Australia Anticancer monoclonal antibodies Market
  • 8.6.5. South Korea Anticancer monoclonal antibodies Market
  • 8.6.6. Rest of Asia Pacific Anticancer monoclonal antibodies Market
• 8.7. Latin America Anticancer monoclonal antibodies Market Snapshot
  • 8.7.1. Brazil Anticancer monoclonal antibodies Market
  • 8.7.2. Mexico Anticancer monoclonal antibodies Market
• 8.8. Middle East & Africa Anticancer monoclonal antibodies Market
  • 8.8.1. Saudi Arabia Anticancer monoclonal antibodies Market
  • 8.8.2. South Africa Anticancer monoclonal antibodies Market
  • 8.8.3. Rest of Middle East & Africa Anticancer monoclonal antibodies Market

Chapter 9. Competitive Intelligence

• 9.1. Key Company SWOT Analysis
  • 9.1.1. Company 1
  • 9.1.2. Company 2
  • 9.1.3. Company 3
• 9.2. Top Market Strategies
• 9.3. Company Profiles
  • 9.3.1. Amgen Inc.
    • 9.3.1.1. Key Information
    • 9.3.1.2. Overview
    • 9.3.1.3. Financial (Subject to Data Availability)
    • 9.3.1.4. Product Summary
    • 9.3.1.5. Recent Developments
  • 9.3.2. Bristol Myers Squibb Company
  • 9.3.3. Eli Lilly and Company
  • 9.3.4. F. Hoffmann-La Roche Ltd.
  • 9.3.5. Genmab AS
  • 9.3.6. Novartis AG
  • 9.3.7. Merck & Co., Inc.
  • 9.3.8. GlaxoSmithKline plc
  • 9.3.9. Johnson & Johnson Corp.
  • 9.3.10. AbbVie, Inc

Chapter 10. Research Process

• 10.1. Research Process
  • 10.1.1. Data Mining
  • 10.1.2. Analysis
  • 10.1.3. Market Estimation
  • 10.1.4. Validation
  • 10.1.5. Publishing
• 10.2. Research Attributes
• 10.3. Research Assumption